Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in
HER2-negative locally advanced or metastatic breast cancer.